Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1799
Source ID: NCT04582448
Associated Drug: Insulin Icodec
Title: A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Insulin icodec
Outcome Measures: Primary: AUCIco,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose, From 0 hours until infinity after trial product administration (pmol\*h/L), Day 1 | Secondary: Cmax,Ico,SD, Maximum observed serum insulin icodec concentration after a single dose, From 0 hours until infinity after trial product administration (pmol/L), Day 1|tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose, From 0 hours until infinity after trial product administration (hours), Day 1
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 25
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2020-10-01
Completion Date: 2021-09-27
Results First Posted:
Last Update Posted: 2023-01-20
Locations: Novo Nordisk Investigational Site, Mainz, 55116, Germany
URL: https://clinicaltrials.gov/show/NCT04582448